{"id":"ct-868","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5782503","moleculeType":null,"molecularWeight":"518.64"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CT-868 is an investigational compound in early clinical development by Carmot Therapeutics. Limited public information is available regarding its precise molecular mechanism and target. The drug is currently in Phase 2 trials, indicating it has completed initial safety and dosage studies.","oneSentence":"CT-868 is a selective inhibitor of a molecular target being developed for metabolic or inflammatory disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:29:41.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05110846","phase":"PHASE2","title":"A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2022-02-22","conditions":"Obesity, Overweight, Type 2 Diabetes Mellitus","enrollment":103},{"nctId":"NCT06062069","phase":"PHASE2","title":"A Study of CT-868 in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2023-10-19","conditions":"Overweight, Obese, Type 1 Diabetes Mellitus","enrollment":111},{"nctId":"NCT04973111","phase":"PHASE1","title":"A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2021-07-16","conditions":"Diabetes","enrollment":32},{"nctId":"NCT05794581","phase":"PHASE1","title":"A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2023-03-21","conditions":"Type 1 Diabetes","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CT-868","genericName":"CT-868","companyName":"Carmot Therapeutics, Inc.","companyId":"carmot-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}